ADCY9 and multiple sclerosis: We only found different levels of complement components for some of their activated forms (i.e., lower aC4 and higher aC9) in multiple sclerosis patients compared to controls but not between relapsing and remitting patients, consistent with more recent data reporting the absence of correlation between complement and disease activity in treatment-naïve early multiple sclerosis patients (22).